コンテンツへスキップ
Merck
  • Prognostic value of rubidium-82 positron emission tomography in patients after heart transplant.

Prognostic value of rubidium-82 positron emission tomography in patients after heart transplant.

Circulation. Cardiovascular imaging (2014-09-04)
Brian A Mc Ardle, Ross A Davies, Li Chen, Gary R Small, Terrence D Ruddy, Girish Dwivedi, Yeung Yam, Haissam Haddad, Lisa M Mielniczuk, Ellamae Stadnick, Renee Hessian, Ann Guo, Rob S Beanlands, Robert A deKemp, Benjamin J W Chow
要旨

Cardiac allograft vasculopathy is a key prognostic determinant after heart transplant. Detection and risk stratification of patients with cardiac allograft vasculopathy are problematic. Positron emission tomography using rubidium-82 allows quantification of absolute myocardial blood flow and may have utility for risk stratification in this population. Patients with a history of heart transplant undergoing dipyridamole rubidium-82 positron emission tomography were prospectively enrolled. Myocardial perfusion and left ventricular ejection fraction were recorded. Absolute flow quantification at rest and after dipyridamole stress as well as the ratio of mean global flow at stress and at rest, termed myocardial flow reserve, were calculated. Patients were followed for all-cause death, acute coronary syndrome, and heart failure hospitalization. A total of 140 patients (81% men; median age, 62 years; median follow-up, 18.2 months) were included. There were 14 events during follow-up (9 deaths, 1 acute coronary syndrome, and 4 heart failure admissions). In addition to baseline clinical variables (estimated glomerular filtration rate, previously documented cardiac allograft vasculopathy), relative perfusion defects, mean myocardial flow reserve, and mean stress myocardial blood flow were significant predictors of adverse outcome. Abnormalities on rubidium-82 positron emission tomography were predictors of adverse events in heart transplant patients. Larger prospective studies are required to confirm these findings.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
カフェイン, anhydrous, 99%, FCC, FG
USP
カフェイン, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
カフェイン, powder, ReagentPlus®
Supelco
カフェイン, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
タンタル(V)エトキシド, 99.98% trace metals basis
USP
カフェイン融点標準品, United States Pharmacopeia (USP) Reference Standard
Supelco
カフェイン, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
カフェイン, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
カフェイン, Sigma Reference Standard, vial of 250 mg
Supelco
融点スタンダード235~237°C, analytical standard
Supelco
Mettler-Toledo®キャリブレーション用物質ME 18872、カフェイン, traceable to primary standards (LGC)
Sigma-Aldrich
カフェイン, anhydrous, tested according to Ph. Eur.
Sigma-Aldrich
カフェイン, SAJ special grade, ≥98.5%
Sigma-Aldrich
カフェイン, meets USP testing specifications, anhydrous
タンタル(V)エトキシド, packaged for use in deposition systems
Sigma-Aldrich
カフェイン, BioXtra
システム適合性用カフェイン, European Pharmacopoeia (EP) Reference Standard
カフェイン, European Pharmacopoeia (EP) Reference Standard